Chemotherapy Combination for Breast Cancer
Author Information
Author(s): Berruti A, Bitossi R, Gorzegno G, Bottini A, Generali D, Milani M, Katsaros D, Rigault de la Longrais I A, Bellino R, Donadio M, Ardine M, Bertetto O, Danese S, Sarobba M G, Farris A, Lorusso V, Dogliotti L
Primary Institution: Azienda Ospedaliera San Luigi
Hypothesis
Does the combination of vinorelbine, paclitaxel, and 5-fluorouracil provide effective treatment for metastatic breast cancer patients pretreated with anthracyclines?
Conclusion
The combination of vinorelbine, paclitaxel, and 5-fluorouracil is effective and manageable for treating metastatic breast cancer in patients previously treated with anthracyclines.
Supporting Evidence
- Objective responses were recorded in 39 of 61 patients (64.0%) assessed by WHO.
- Complete remission occurred in 15 (24.6%) patients according to WHO criteria.
- The median time to progression was 10.6 months.
- The median overall survival was 27.3 months.
- Grade 3/4 leucopenia was observed in 52.5% of patients.
Takeaway
This study tested a new mix of medicines to help women with advanced breast cancer who had already received other treatments, and it worked well for many of them.
Methodology
Patients received a combination of vinorelbine, paclitaxel, and continuous infusion of 5-fluorouracil, with response evaluated by WHO and RECIST criteria.
Potential Biases
Potential selection bias due to the specific inclusion criteria for patients.
Limitations
The study did not include a control group and was limited to patients who had previously received anthracyclines.
Participant Demographics
All participants were women aged 18 and older with histologically confirmed advanced breast cancer.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 51.7–76.3%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website